What it means in practice
Part D drug plans are sold separately from Parts A and B. Each plan has its own monthly premium (typically $0-$80), its own formulary (the list of covered drugs), its own pharmacy network, and its own tier-based cost-sharing. The same drug can be a $5 copay on one plan, a $50 copay on another, and not covered at all on a third. Annual re-evaluation during Open Enrollment (Oct 15-Dec 7) matters: formularies change every year, and a plan that was the cheapest for your parent's medication list this year may not be next year.
The Inflation Reduction Act of 2022/2025 reshaped Part D dramatically. The "donut hole" coverage gap (which used to leave patients with chronic conditions paying full cost between $4,000-$8,000 in annual drug spending) is gone. Out-of-pocket Part D costs are now capped at $2,000/year. Patients can spread the $2,000 across the year through Medicare's "Smoothed Payment" option instead of paying the full out-of-pocket as drugs are filled.
The Inflation Reduction Act also lets Medicare negotiate prices for the highest-cost drugs — the first 10 drugs (Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, Fiasp/NovoLog) have negotiated prices effective 2026. More drugs get negotiated each year. For patients on these drugs, the savings can be substantial.
Low-income subsidies (called "Extra Help" or LIS) cover most or all Part D costs for patients under income and asset thresholds. Many eligible patients don't know they qualify; the Social Security Administration administers the application. The State Health Insurance Assistance Program (SHIP) provides free counseling to help families pick a Part D plan and apply for LIS.